Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study

Published Date: 14 Jun 2024

Second-gen ALK inhibitor induces high response rate, associated with impressive survival

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Why preventive mastectomy isn't offered to everyone at risk

2.

Low Income, Education Tied to Depression in Older Adults

3.

Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study

4.

A new theranostic drug targets different cancer types.

5.

Effective Intralesional Melanoma Therapy May Involve Systemic Effects.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot